Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer.

Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M.

Breast Cancer Res Treat. 1989 Dec;14(3):289-98.

PMID:
2575406
2.

Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide.

Anderson E, Ferguson JE, Morten H, Shalet SM, Robinson EL, Howell A.

Eur J Cancer. 1993;29A(2):209-17.

PMID:
8422285
3.

The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.

Lamberts SW, Zweens M, Klijn JG, van Vroonhoven CC, Stefanko SZ, Del Pozo E.

Clin Endocrinol (Oxf). 1986 Aug;25(2):201-12.

PMID:
2878748
4.

Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.

Pieters GF, van Liessum PA, Smals AG, van Gennep JA, Benraad TJ, Kloppenborg PW.

Acta Endocrinol Suppl (Copenh). 1987;286:9-18.

PMID:
2892339
5.

Somatostatin analog treatment of acromegaly: new aspects.

Lamberts SW, del Pozo E.

Horm Res. 1988;29(2-3):115-7.

PMID:
2900190
6.

Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.

Fredstorp L, Kutz K, Werner S.

Clin Endocrinol (Oxf). 1994 Jul;41(1):103-8.

PMID:
8050122
7.

Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments.

Pannuti F, Martoni A, Farabegoli G, Piana E.

Chemioterapia. 1985 Apr;4(2):127-34.

PMID:
3159487
8.

Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology.

Di Leo A, Ferrari L, Bajetta E, Bartoli C, Vicario G, Moglia D, Miceli R, Callegari M, Bono A.

Breast Cancer Res Treat. 1995 Jun;34(3):237-44.

PMID:
7579488
9.
10.
11.

Abnormal growth hormone responsiveness to stimuli in women with active celiac sprue.

Peracchi M, Molteni N, Cantalamessa L, Bardella MT, Peracchi G, Orsatti A, Faggioli P, Bianchi PA.

Am J Gastroenterol. 1992 May;87(5):580-3.

PMID:
1595643
12.

A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.

Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G.

Eur J Endocrinol. 1999 Sep;141(3):267-71.

13.
14.

Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests.

Nortier JW, Croughs RJ, Donker GH, Thijssen JH, Schwarz F.

Acta Endocrinol (Copenh). 1984 Jun;106(2):175-83.

PMID:
6145276
15.

Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.

O'Byrne KJ, Dobbs N, Propper DJ, Braybrooke JP, Koukourakis MI, Mitchell K, Woodhull J, Talbot DC, Schally AV, Harris AL.

Br J Cancer. 1999 Mar;79(9-10):1413-8.

16.
17.

The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome.

Piaditis GP, Hatziioanidis AH, Trovas GP, Misichronis GS, Kounadi TG, Devetzaki OA, Andronis CK, Rangou DB, Chlouverakis CS.

Clin Endocrinol (Oxf). 1996 Nov;45(5):595-604.

PMID:
8977757
18.

Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer.

De Marinis L, Mancini A, Izzi D, Bianchi A, Giampietro A, Fusco A, Liberale I, Rossi S, Valle D.

Clin Endocrinol (Oxf). 2000 Jun;52(6):681-5.

PMID:
10848871
19.

Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.

Christensen SE, Weeke J, Orskov H, Møller N, Flyvbjerg A, Harris AG, Lund E, Jørgensen J.

Clin Endocrinol (Oxf). 1987 Sep;27(3):297-306.

PMID:
2892599
20.

A comparison among the effectiveness of growth hormone suppression in active acromegaly of bromocriptine and long acting somatostatin analogue (SMS 201-995).

Popović V, Nesović M, Mićić D, Kendereski A, Djordjević P, Manojlović D, Mićić J.

Exp Clin Endocrinol. 1990 Apr;95(2):251-7.

PMID:
1973122
Items per page

Supplemental Content

Write to the Help Desk